Remove Clinical Development Remove Clinical Research Remove Hormones
article thumbnail

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval

Pharmaceutical Technology

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). Douglas collaborates with scientific researchers and external medical experts to advance clinical research. It operates in New Zealand, Fiji and the US.

article thumbnail

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval

Pharmaceutical Technology

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). Douglas collaborates with scientific researchers and external medical experts to advance clinical research. It operates in New Zealand, Fiji and the US.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck’s Keytruda flunks another prostate cancer test

pharmaphorum

Merck has said it will abandon the KEYNOTE-991 study of PD-1 inhibitor Keytruda (pembrolizumab) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) after it showed no benefit on either overall survival (OS) or radiographic progression-free survival (rPFS) when the data was analysed midway though.

article thumbnail

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.

article thumbnail

Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts

XTalks

Amgens randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of 30 or 27, respectively, with at least one obesity-related comorbidity.

Trials 104
article thumbnail

Lumos Pharma’s Commitment to Innovation in Rare Pediatric Growth Disorders

XTalks

For example, pediatric growth hormone deficiency (PGHD) affects approximately one in 3,500 to one in 10,000 children. Existing therapeutic options for PGHD consist of injectable formulations of recombinant human growth hormone (rhGH), administered subcutaneously either on a daily or weekly basis.

article thumbnail

Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts

XTalks

Amgen’s randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of ≥30 or ≥27, respectively, with at least one obesity-related comorbidity.

Trials 96